Pioneering psychedelic researcher once again paves the way with historic psilocybin study for end of life patients

Lucid News report on the new multi-centre study aiming to take psychedelic-assisted psychotherapy out into palliative care. They write: "The Lundquist Institute for Biomedical Innovation announced last month that Grob and Bossis will lead a new multi-site clinical trial to study the effectiveness and safety of psilocybin to treat terminally ill people with psychological distress. The new clinical trial will be funded by an anonymous $1.75 million donation to The Lundquist Institute. The funds will also be used to develop education and outreach programs on the use of psilocybin for palliative care, a medical specialty that focuses on relieving suffering and improving the quality of life for people with a serious illness. The Lundquist Institute study will be the first to investigate a psychedelic substance for palliative care and the first to conduct new clinical trials to move the findings of the 2016 trials forward. This research comes at a critical time as a wave of emerging companies and organizations are investigating the use of psychedelics for mental health treatments."

Previous
Previous

Magic mushrooms contain more than just psilocybin

Next
Next

Can psychedelics offer a new treatment for eating disorders?